To the Editor: Dr Als-Nielsen and colleagues1 stated that "[i]n principle, about half of all
trials should favor the control intervention." The authors' findings reflect
that expectation that "The experimental drug was recommended as treatment
of choice in . . . 51% of trials funded by for-profit organizations." The
authors do not explain, however, why the trials performed by nonprofit organizations
had a lower percentage.